Daewoong Pharma (069620)

Currency in KRW
155,100
+5,100(+3.40%)
Closed·
069620 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
151,900155,700
52 wk Range
128,100199,400
Key Statistics
Bid/Ask
155,000.00 / 155,100.00
Prev. Close
155,100
Open
151,900
Day's Range
151,900-155,700
52 wk Range
128,100-199,400
Volume
43.25K
Average Vol. (3m)
35.58K
1-Year Change
19.3077%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
069620 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
218,000
Upside
+40.55%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Daewoong Pharma News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Employees
1644

Compare 069620 to Peers and Sector

Metrics to compare
069620
Peers
Sector
Relationship
P/E Ratio
9.1x13.1x−0.5x
PEG Ratio
0.010.120.00
Price / Book
1.8x1.2x2.6x
Price / LTM Sales
1.1x0.8x3.2x
Upside (Analyst Target)
35.4%29.3%47.6%
Fair Value Upside
Unlock18.3%6.1%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 218,000
(+40.55% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 17,021.64%
Dividend Yield
0.40%
Industry Median 1.01%
Annualized Payout
600.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Mar 18, 2026
EPS / Forecast
7,810.00 / --
Revenue / Forecast
355.8B / 379.82B
EPS Revisions
Last 90 days

069620 Income Statement

People Also Watch

221,500
298050
+2.31%
50,600
229640
+13.71%
148,000
006280
+2.78%
24,900
001800
+1.43%
27,750
002790
+1.65%

FAQ

What Is the Daewoong Pharma (069620) Stock Price Today?

The Daewoong Pharma stock price today is 155,100 KRW.

What Stock Exchange Does Daewoong Pharma Trade On?

Daewoong Pharma is listed and trades on the Seoul Stock Exchange.

What Is the Stock Symbol for Daewoong Pharma?

The stock symbol for Daewoong Pharma is "069620."

Does Daewoong Pharma Pay Dividends? What’s The Current Dividend Yield?

The Daewoong Pharma dividend yield is 0.39%.

What Is the Daewoong Pharma Market Cap?

As of today, Daewoong Pharma market cap is 1.78T KRW.

What Is Daewoong Pharma's Earnings Per Share (TTM)?

The Daewoong Pharma EPS (TTM) is 17,022.

When Is the Next Daewoong Pharma Earnings Date?

Daewoong Pharma will release its next earnings report on May 18, 2026.

From a Technical Analysis Perspective, Is 069620 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Daewoong Pharma Stock Split?

Daewoong Pharma has split 6 times.

How Many Employees Does Daewoong Pharma Have?

Daewoong Pharma has 1644 employees.

What is the current trading status of Daewoong Pharma (069620)?

As of Apr 15, 2026, Daewoong Pharma (069620) is trading at a price of 155,100 KRW, with a previous close of 155,100 KRW. The stock has fluctuated within a day range of 151,900 KRW to 155,700 KRW, while its 52-week range spans from 128,100 KRW to 199,400 KRW.

What Is Daewoong Pharma (069620) Price Target According to Analysts?

The average 12-month price target for Daewoong Pharma is 218,000 KRW, with a high estimate of 250000 KRW and a low estimate of 200000 KRW. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +40.55% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.